Entasis Therapeutics (ETTX) News Today → Top 5 Tech Stocks to Buy for 2024 (From Daily Market Alerts) (Ad) Free ETTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative July 18, 2022 | insidermonkey.comHedge Fund and Insider Trading News: D.E. Shaw, Elliott Management, Millennium Management, Marshall Wace LLP, Three Arrows Capital, Entasis Therapeutics Holdings Inc. (ETTX), Gossamer Bio Inc (GOSS), and MoreJuly 11, 2022 | marketbeat.comTrading was temporarily halted for "ETTX" at 07:07 PM with a stated reason of "News pending."June 9, 2022 | finance.yahoo.comEntasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual ConferenceJune 9, 2022 | finance.yahoo.comEntasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual ConferenceJune 9, 2022 | apnews.comINVESTIGATION ALERT: Halper Sadeh LLP Investigates MANT, ETTX, CTEKJune 3, 2022 | apnews.comScott+Scott Attorneys at Law LLP Investigates Innoviva Buyout of Entasis – ETTXMay 31, 2022 | apnews.comSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates ETTX, CDEV, CTEKMay 29, 2022 | marketbeat.comShort Interest in Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) Decreases By 35.4%Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX - Get Rating) saw a significant decline in short interest during the month of May. As of May 15th, there was short interest totalling 105,100 shares, a decline of 35.4% from the April 30th total of 162,700 shares. Based on an average daily trading volume, of 169,900 shares, the short-interest ratio is presently 0.6 days. Currently, 0.7% of the company's shares are short sold.May 25, 2022 | finance.yahoo.comBiotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers UpdatesMay 25, 2022 | apnews.comENTASIS ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of ETTX and Encourages Investors to Contact the FirmMay 24, 2022 | apnews.comSHAREHOLDER ALERT: Halper Sadeh LLP Investigates ETTX, CTEK, VSAT, WLL, LHCGMay 24, 2022 | finance.yahoo.comAstraZeneca spinout, based in Waltham, acquired at 60% premiumMay 24, 2022 | benzinga.comInvestor Alert - The M&A Class Action Firm Announces an Investigation of Entasis Therapeutics Holdings Inc. - ETTXMay 23, 2022 | apnews.comETTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Entasis Therapeutics Holdings Inc. Is Fair to ShareholdersMay 23, 2022 | marketbeat.comTrading was temporarily halted for "ETTX" at 08:05 AM with a stated reason of "News pending."May 19, 2022 | finance.yahoo.comAntibiotic resistance efforts get a boost as CARB-X gets $370MMay 17, 2022 | finance.yahoo.comEntasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual ConferenceMay 17, 2022 | finance.yahoo.comEntasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual ConferenceApril 27, 2022 | finance.yahoo.comEntasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Business UpdateApril 27, 2022 | finance.yahoo.comEntasis Therapeutics Announces First Quarter 2022 Financial Results and Provides Business UpdateApril 26, 2022 | finance.yahoo.comEntasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 ConferenceApril 18, 2022 | baystreet.caEntasis Flat on DataApril 18, 2022 | finance.yahoo.comEntasis Therapeutics Presents SUL-DUR Topline Data from Phase 3 ATTACK Trial at ECCMID 2022 ConferenceMarch 16, 2022 | benzinga.comAlliance Global Partners Downgrades Entasis Therapeutics Hldg to NeutralMarch 16, 2022 | marketbeat.comEntasis Therapeutics (NASDAQ:ETTX) Downgraded by Alliance Global Partners to NeutralAlliance Global Partners downgraded Entasis Therapeutics from a "buy" rating to a "neutral" rating in a report on Wednesday.March 15, 2022 | marketwatch.comEntasis Shares Rise After Innoviva Raises Buyout Price to $2 a ShareMarch 8, 2022 | marketbeat.comEntasis Therapeutics (NASDAQ:ETTX) Rating Increased to Buy at Zacks Investment ResearchZacks Investment Research raised Entasis Therapeutics from a "hold" rating to a "buy" rating and set a $2.00 target price on the stock in a research report on Tuesday.March 8, 2022 | benzinga.comWedbush Downgrades Entasis Therapeutics Hldg to Neutral, Lowers Price Target to $1.8March 4, 2022 | benzinga.comHC Wainwright & Co. Downgrades Entasis Therapeutics Hldg to Neutral, Lowers Price Target to $1.8March 3, 2022 | finance.yahoo.comEntasis Therapeutics Announces Year End 2021 Financial Results and Provides Business UpdateFebruary 3, 2022 | nasdaq.comPre-market Movers: MDJH, ELMS, EXC, PYPL, PHAR…February 2, 2022 | finance.yahoo.comEntasis Therapeutics Receives Acquisition Proposal from Existing Majority Stockholder Innoviva Inc.February 2, 2022 | seekingalpha.comEntasis gains on buyout proposal from InnovivaJanuary 12, 2022 | nasdaq.comEntasis Therapeutics Holdings Inc. Common Stock (ETTX)January 10, 2022 | finance.yahoo.comEntasis Therapeutics to Participate in H.C. Wainwright BioConnect 2022November 12, 2021 | nasdaq.comIs Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Deliver On Growth Plans?November 12, 2021 | finance.yahoo.comHow Many Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) Shares Do Institutions Own?November 4, 2021 | finance.yahoo.comEntasis Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business UpdateOctober 28, 2021 | finance.yahoo.comEntasis Therapeutics to Report Third Quarter 2021 Results and Host Conference Call November 4, 2021October 20, 2021 | finance.yahoo.comEntasis' (ETTX) Phase III Study on Infection Drug Meets GoalOctober 19, 2021 | finance.yahoo.comEntasis Shares Rally On Positive Data From Drug-Resistant Bacterial Infection CandidateOctober 19, 2021 | finance.yahoo.comZai Lab and Entasis Therapeutics Announce Positive Topline Results for Sulbactam-Durlobactam (SUL-DUR) from Phase 3 ATTACK TrialOctober 19, 2021 | apnews.comEntasis Therapeutics announces positive topline results for sulbactam-durlobactam (SUL-DUR)October 19, 2021 | msn.comBRIEF-Entasis Therapeutics Announces Positive Topline Results For Sulbactam-Durlobactam From Phase 3 Attack TrialOctober 18, 2021 | finance.yahoo.comEntasis Therapeutics announces positive topline results for sulbactam-durlobactam (SUL-DUR) from Phase 3 ATTACK trialOctober 18, 2021 | marketbeat.comTrading was temporarily halted for "ETTX" at 04:10 PM with a stated reason of "News pending."September 23, 2021 | finance.yahoo.comEntasis Therapeutics to Participate in the Cantor Fitzgerald Virtual Global Healthcare ConferenceSeptember 23, 2021 | benzinga.comEntasis Therapeutics to Participate in the Cantor Fitzgerald Virtual Global Healthcare ConferenceSeptember 17, 2021 | nz.finance.yahoo.comModerna Highlights New Clinical Data on its COVID-19 VaccineSeptember 16, 2021 | msn.comWhy Are Entasis Therapeutics Shares Moving Higher On Thursday? Get Entasis Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ETTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Top 5 AI Stocks to Buy for 2024 (Ad)5 Best AI Stocks to Invest In Investors are getting very rich in AI stocks right now. Wall Street legend is giving away the name and ticker of the little-known AI stock Wall Street is currently buying hand-over-fist. Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In" ETTX Media Mentions By Week ETTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ETTX News Sentiment▼0.000.56▲Average Medical News Sentiment ETTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ETTX Articles This Week▼00▲ETTX Articles Average Week Get Entasis Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ETTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Allakos News Today Connect Biopharma News Today BeyondSpring News Today Oramed Pharmaceuticals News Today Adicet Bio News Today Assertio News Today Relmada Therapeutics News Today PMV Pharmaceuticals News Today Citius Pharmaceuticals News Today Corvus Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ETTX) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden FINISHED On June 13th?Paradigm PressTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTop 5 Tech Stocks to Buy for 2024Daily Market AlertsTop 5 AI Stocks to Buy for 2024Market Moving Trendsis this a buy and hold stock?Tips4TradersWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entasis Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
